SOLIGENIX INC (SNGX:NASDAQ)
$0.3636 0.017 (4.9048%)
Analysed SOLIGENIX INC (SNGX:NASDAQ) News Sources
SNGX Phase 3 Trial Halted on HyBryte
28-04-2026
advfn.com
SNGX: Interim Analysis for Phase 3 CTCL Study in 2Q26
06-04-2026
yahoo.com
Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
21-04-2026
yahoo.com
SNGX: Continuing to Analyze FLASH2 Data
14-05-2026
yahoo.com
SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail Frenzy
27-05-2026
stocktwits.com
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
08-06-2026
yahoo.com
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
07-08-2026
yahoo.com
Soligenix culls topical lymphoma asset after Phase III miss
10-08-2026
clinicaltrialsarena.com
SNGX: Applying for Vaccine Development Funding for Ebola Vaccine
12-08-2026
yahoo.com
Radiotherapy-Induced Oral Mucositis Market Set for Strong Growth Through 2036, Driven by Emerging Therapies and Rising Cancer Burden | DelveInsight
20-08-2026
yahoo.com
What is the current price of SOLIGENIX INC (SNGX:NASDAQ)?
The current price of SOLIGENIX INC (SNGX:NASDAQ) is $0.3636.
SOLIGENIX INC (SNGX:NASDAQ) absolute price change since previous trading day?
The absolute price change of SOLIGENIX INC (SNGX:NASDAQ) since the previous trading day is $0.017.
SOLIGENIX INC (SNGX:NASDAQ) percentage price change since previous trading day?
The percentage price change of SOLIGENIX INC (SNGX:NASDAQ) since the previous trading day is 4.9048%.
What is the most recent average sentiment score for SOLIGENIX INC (SNGX:NASDAQ)?
The most recent average sentiment score for SOLIGENIX INC (SNGX:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for SOLIGENIX INC (SNGX:NASDAQ)?
The most recent sentiment for SOLIGENIX INC (SNGX:NASDAQ) is .
SEC-8K** Filing Available For SOLIGENIX INC (SNGX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.